Dyne Therapeutics (NASDAQ:DYN) Director Brian Posner Acquires 2,500 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner bought 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average price of $17.48 per share, with a total value of $43,700.00. Following the completion of the acquisition, the director owned 22,500 shares of the company’s stock, valued at $393,300. This trade represents a 12.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Dyne Therapeutics Trading Down 7.4%

NASDAQ:DYN opened at $17.04 on Friday. The firm has a market cap of $2.82 billion, a PE ratio of -5.29 and a beta of 1.09. The stock has a fifty day moving average price of $18.28 and a 200 day moving average price of $18.28. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the previous year, the business earned ($1.05) earnings per share. Sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently bought and sold shares of DYN. AQR Capital Management LLC purchased a new stake in Dyne Therapeutics during the 1st quarter worth about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Dyne Therapeutics by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after buying an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after buying an additional 366,183 shares during the last quarter. Caxton Associates LLP purchased a new stake in Dyne Therapeutics during the 1st quarter worth about $157,000. Finally, Creative Planning increased its position in shares of Dyne Therapeutics by 23.8% during the second quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after purchasing an additional 2,797 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on DYN. Sanford C. Bernstein lifted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Evercore set a $33.00 price target on Dyne Therapeutics in a report on Friday, May 15th. Chardan Capital reaffirmed a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a report on Monday, March 9th. Finally, Morgan Stanley decreased their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.